Personalized DNA Vaccine Shows Promise in Treating Aggressive Brain Cancer in Early Trial

A new experimental approach using a personalized DNA vaccine has shown encouraging signs of safety and effectiveness in a small group of patients battling a particularly aggressive form of brain cancer. The findings, published in the journal Nature Cancer, offer a glimmer of hope for a disease that has seen few treatment advances in decades.

What the Study Found

Researchers from Washington University School of Medicine in St. Louis tested a custom-made DNA vaccine in nine patients with a type of brain cancer called MGMT-unmethylated glioblastoma. This specific subtype is notoriously difficult to treat because it does not respond well to standard chemotherapy drugs.

The vaccine did not cause any serious side effects. More importantly, it appeared to help patients live longer than what doctors typically expect. The median overall survival—meaning the time when half of the patients had passed away—was 16.3 months. That is better than the usual survival time of about 12 months for this patient group.

Perhaps the most striking finding: one-third of the patients, or 33%, were still alive two years after their diagnosis. One patient even survived more than four years from the time of their initial surgery. For context, co-author Dr. Albert H. Kim noted that normally only about 10% to 15% of patients with this cancer live to the two-year mark.

Understanding the Numbers

The study also tracked how long patients went without their cancer getting worse. The median progression-free survival was 8.5 months. At six months, about 66.7% of patients had not seen their cancer progress.

Dr. Tanner M. Johanns, the lead author, explained that this personalized vaccine approach could become a valuable treatment option for glioblastoma patients. The team published their results in Nature Cancer.

Why This Matters for Patients

Glioblastoma is the most common and most deadly form of brain cancer in adults. About 12,000 people in the United States are diagnosed with it each year. The average survival time is roughly 12 to 18 months, even with aggressive treatment that includes surgery, radiation, and chemotherapy.

The MGMT-unmethylated subtype accounts for about half of all glioblastoma cases. These patients have a gene marker that makes their tumors resistant to temozolomide, the standard chemotherapy drug. This means they have even fewer treatment options and a worse outlook than other glioblastoma patients.

Dr. Kim described the situation bluntly: “Glioblastoma is a very challenging cancer. If you take all-comers, the median survival is somewhere around a year and a half. And there’s a subset of these glioblastoma patients—MGMT-unmethylated—who won’t respond to chemotherapy. That MGMT-unmethylated subgroup does even worse. So, this is a bad disease, and it needs an urgent set of solutions.”

How the Vaccine Works

The vaccine targets structures called neoantigens. These are unique proteins found only on a person’s cancer cells. Think of them as red flags that signal to the immune system: “This cell is dangerous and needs to be destroyed.”

To create the vaccine, the research team first took samples from different parts of each patient’s tumor. They then designed a personalized DNA vaccine containing up to 40 neoantigens. The goal was to train the patient’s own immune system to recognize and attack their specific cancer.

This approach is different from other cancer immunotherapies. Drugs called immune checkpoint inhibitors have worked wonders for cancers like melanoma and lung cancer. But they have largely failed in glioblastoma. Dr. Kim explained that glioblastoma is considered an “immune cold” tumor, meaning it is very good at hiding from the immune system. The personalized vaccine is designed to warm up that immune response.

What Experts Say About This Approach

Cancer experts not involved in this study generally agree that personalized vaccines represent a promising frontier in oncology. The idea of training a patient’s immune system to fight their specific tumor has been a long-standing goal in cancer research. However, experts also caution that this is an early-phase trial with only nine patients. Larger studies are needed to confirm whether the survival benefits are real and not just due to chance or patient selection.

Dr. Kim himself urged caution: “The trial was small, so I don’t want to oversell, but I think [the 2-year survival rate of 33%] suggests a signal.”

The challenge of treating glioblastoma is immense. Tumors are located inside the brain, which has special barriers that limit what drugs and immune cells can enter. Glioblastoma cells also tend to be very diverse, meaning different parts of the same tumor can have different genetic mutations. This makes it hard for any single treatment to kill all the cancer cells.

Details of the Trial

The nine patients in the study had an average age of 59 years. About two-thirds were male, and all were white. This lack of diversity is a limitation, as cancer treatments can affect people of different backgrounds differently.

Patients received their first vaccine injection about 10 weeks after undergoing surgery and radiation therapy. After that, they received the vaccine every three weeks for a nine-week period. Then, they continued getting the vaccine every nine weeks for as long as they were able to participate. On average, patients received four doses total.

The vaccine proved safe. There were no unexpected toxicities or dose-limiting side effects. Most of the reported side effects were mild—classified as grade 1—and mainly involved reactions at the injection site, such as redness or soreness.

Importantly, all but one patient showed an increase in immune cell activity after receiving the vaccine. The one patient who did not show this response was taking an immune-suppressing steroid, which is commonly used to reduce brain swelling in glioblastoma patients. This suggests the steroid may have dampened the vaccine’s effectiveness.

Practical Takeaways for Readers

While this news is promising, it is important to keep several things in mind:

• This is an early-stage trial. Phase 1 trials are designed primarily to test safety, not to prove that a treatment works. Larger phase 2 and phase 3 trials are needed.
• The vaccine is personalized. This means it cannot be mass-produced. Each vaccine is custom-made for one patient, which makes it expensive and time-consuming to produce.
• It is not yet available. The vaccine is still experimental. Patients cannot get it outside of a clinical trial. An ongoing phase 1 trial is now testing this vaccine in combination with a PD-1 blockade therapy, which is another type of immunotherapy.
• Standard treatments remain essential. For now, surgery, radiation, and chemotherapy remain the backbone of glioblastoma treatment. Patients should not abandon proven therapies for experimental ones.

Looking Ahead

Dr. Kim drew a parallel to other cancers that were once considered hopeless. He pointed to melanoma, which 15 years ago had a devastating prognosis—especially if it spread to the brain. Then immune checkpoint inhibitors arrived, and the outlook transformed dramatically. Former President Jimmy Carter, who had melanoma that metastasized to his brain at age 90, lived to be 100 thanks to these treatments.

“Transformation, I think, is also just around the corner for glioblastoma patients,” Dr. Kim said.

For patients and families facing a glioblastoma diagnosis, this study offers a reason for cautious optimism. The field is moving forward, and personalized approaches like this DNA vaccine represent a new direction in the fight against one of medicine’s toughest cancers.

If you or a loved one has been diagnosed with glioblastoma, talk to your oncologist about whether clinical trials might be an option. Websites like ClinicalTrials.gov list ongoing studies that may be recruiting participants. While no single breakthrough will help everyone, each small step brings researchers closer to better treatments and, eventually, better outcomes.

Source: MedPage Today